Clinical Trials
6 trialsNCT07581821 2026-05-12
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT07540390 2026-04-22
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07320963 2026-03-20
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06851247 2025-02-28
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 2 Recruiting
NCT04996758 2024-12-12
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
Sun Yat-sen University
Phase 2 Completed
NCT03906058 2023-10-25
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
Sun Yat-sen University
Phase 2 Completed